Alentis Therapeutics

Our Chief Scientific Officer, Alberto Toso will present at the 1st Claudin-Targeted Therapies Summit held virtually on December 4-5. Great to see so many companies joining the exciting Claudin space! Alberto will present our pipeline of antibody-drug conjugates (#ADC) and antibodies targeting Claudin-1, an extraordinary target that plays a key role in #oncology and #fibrosis. Learn more here: https://lnkd.in/eEPJaTfp #AlentisTherapeutics #Claudin #CLDN1 #CLDN18.2 #CLDN6

Good news! The FDA granted Fast Track designation to ALE.P02, our first-in-class antibody-drug conjugate (ADC) targeting Claudin-1. The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cell tumors, irrespective of the organ of origin. Watch the video with Stella Augustus, our Head of Regulatory Affairs, on why this designation is remarkable. A Phase 1/2 clinical trial of ALE.P02 is planned to start Q1 2025 in patients with CLDN1+ lung, head and neck, cervical or esophageal squamous cancers. Read the full press release: https://lnkd.in/edVdnbkQ #AlentisTherapeutics #FastTrack #FDA #ADC #CLDN1 #Claudin #Oncology

Geoffrey Teixeira, our SVP Head of Fibrosis will represent Alentis at the Antifibrotic Drug Development Summit #AFDD2024. Geoffrey will give a presentation titled: ‘Examining Anti-Claudin-1 (#CLDN1) Monoclonal Antibodies in Development for Liver, Kidney & Lung Fibrosis as a Novel Mechanism to Reverse Fibrosis’. The conference is held November 19-21 in Boston, MA. More information: www.afdd-summit.com #AlentisTherapeutics #Claudin #Fibrosis #DrugDevelopment

🚀 Proud moment for Alentis! Our Series D financing was featured on the Nasdaq Tower in Times Square, NYC! A huge thank you to everyone who helped make this possible. Stay tuned as we continue advancing our innovative antibody-drug conjugate (ADC) treatments for cancer. Exciting times ahead! Learn more: https://lnkd.in/eBaY24ue #AlentisTherapeutics #ADC #TimesSquare #NYC

We are delighted to announce the successful closing of an oversubscribed Series D financing, raising $181.4M to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. The funding was supported by a syndicate of top-tier biotech investors including OrbiMed as lead and Novo Holdings and JEITO as co-leads as well as substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital Management, and Catalio Capital Management. This financing is a testament to the transformational potential of CLDN1 targeted medicine in oncology, in particular our first-in-class antibody-drug conjugates (#ADCs) ALE.P02 and ALE.P03. We’re excited to start Phase 1/2 clinical trials for both programs in 2025. Read the full press release: https://lnkd.in/eVSGPG5G We extend our deepest gratitude to our investors for their trust and support. Together we are making a difference 🌍💙 #AlentisTherapeutics #Biotech #Funding #Healthcare #LifeSciences #ADC #CLDN1 #Claudin

We are excited to announce Alentis management is heading to the Jefferies London Healthcare Conference! Representing the company: Roberto Iacone, CEO, Rizwan Velji, CBO, and Jonathan Freve, CFO. We're looking forward to engaging with industry leaders, investors, and partners at this important event. #AlentisTherapeutics #London #Biotech #Partnering #JefferiesHealthcare

Congratulations Vincent Anquetil for your excellent work!

Proud that we were invited to present among the top companies and KOLs in the fibrosis field at the International Conference on Tissue Repair, Regeneration, and Fibrosis! Geoffrey Teixeira, our SVP Head of Fibrosis, will give a presentation titled: ‘Targeting Claudin-1 as a novel therapeutic approach to reverse organ fibrosis’, where he will discuss our clinical-stage mAb lixudebart (ALE.F02) developed for kidney, liver and lung #fibrosis. The conference is held Oct 22-27 in Heraklion, Greece. Find more information on the conference here: https://lnkd.in/eEW7B6Ra #AlentisTherapeutics #Claudin #CLDN1

Good news! The #FDA cleared the IND application for ALE.P02. Proud that we are taking the very first anti-CLDN1 antibody-drug conjugate (ADC) to the clinic. A Phase 1/2 clinical trial in patients with CLDN1+ squamous tumors is expected to start during the first quarter of 2025. “Anti-CLDN1 ADCs are exciting because they address the urgent need for novel targets in the ADC space,” added Tony Mok, Professor of Clinical Oncology. “ALE.P02 is particularly promising for squamous cancers, including HNSCC and NSCLC, where CLDN1 is often overexpressed. The unmet medical need in these indications is significant, and I look forward to the results of the Phase 1/2 study.” Read the full press release: https://lnkd.in/eQU3Hd5y #AlentisTherapeutics #Biotech #ADC #Oncology #Claudin #CLDN1 #SquamousCancer #SolidTumor

Our CEO, Roberto Iacone is presenting during the Oppenheimer & Co. Inc. Private Life Sciences Company Showcase in New York on October 1st. The presentation will focus on our novel ADCs for Claudin-1 positive solid tumors. #AlentisTherapeutics #Biotech #ADC